| Drug / Therapy | mRNA-4157 + pembrolizumab |
| Indication | adjuvant melanoma |
| Decision Type | PDUFA |
| Conditions | adjuvant melanoma |
| Interventions | mRNA-4157 + pembrolizumab |
BioNTech SE (BNTX) operates in the mRNA Therapeutics sector. The current BTS Score is 20 (Grade: F).
Biotech companies frequently raise capital through secondary offerings, ATM programs, and convertible notes. Before or after major FDA decisions, dilution events are common. Understanding a company's dilution history is critical for managing risk around catalyst dates.
The PDUFA date for mRNA-4157 + pembrolizumab by BioNTech SE (BNTX) is scheduled for January 15, 2027. This is the target date for the FDA to make a decision on this application.
mRNA-4157 + pembrolizumab is being developed by BioNTech SE for the treatment of adjuvant melanoma. It is under FDA review.
If mRNA-4157 + pembrolizumab receives FDA approval, BioNTech SE (BNTX) would be able to market the drug in the United States for adjuvant melanoma. This typically leads to significant stock price movement for biotech companies. Investors should monitor the PDUFA date closely.
Biotech companies often raise capital through share offerings, which can dilute existing shareholders. You can check the current dilution risk for BNTX on DilutionWatch at dilutionwatch.com/stock/BNTX.html.
You can view the full BiotechSigns company profile for BioNTech SE (BNTX) at biotechsign.com/app/company/BNTX, which includes the BTS Score, signal history, clinical trial data, and insider trading activity.
This page is for informational purposes only and does not constitute investment advice. FDA decision dates are subject to change. Clinical trial outcomes are inherently uncertain. Biotech stocks are highly volatile — past performance does not guarantee future results. Always consult a qualified financial advisor before making investment decisions. BiotechSigns is not a registered investment advisor.